Latest Conference Articles

Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor­–positive metastatic breast cancer.

An updated analysis of the phase 1 SURPASS trial showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease.

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Neoadjuvant talimogene laherparepvec plus surgery provided sustained, durable improvements in efficacy vs surgery alone in patients with resectable stage IIIB to IVM1a melanoma.

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.

Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.

Although the primary end points of the phase 3 LEAP-002 trial did not meet prespecified statistical significance with regard to survival benefit achieved with lenvatinib plus pembrolizumab, the median overall survival observed with lenvatinib monotherapy supports its role as a standard of care in frontline advanced hepatocellular carcinoma treatment.

A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.

Nirogacestat led to a 71% reduction in the risk of disease progression or death compared with placebo in patients with progressive desmoid tumors.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

The investigational carcinoembryonic antigen claudin 6 (CLDN6)–directed CAR T-cell therapy BNT211-01 displayed clinical activity both as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Adding oleclumab to durvalumab and chemotherapy did not increase the clinical benefit rate vs durvalumab plus chemotherapy alone as a first-line treatment for patients with advanced triple-negative breast cancer.

Sacituzumab govitecan generated statistically significant and clinically meaningful benefits in overall survival and responses vs physician’s choice of treatment in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were resistant to endocrine therapy.

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

Rhenium-186 nanoliposome administered at doses exceeding 100 Gy demonstrated promising safety and efficacy results in patients with recurrent glioma.

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.

Rucaparib elicited a progression-free survival benefit and comparable overall survival (OS) vs chemotherapy in patients with BRCA1/2-mutated, relapsed ovarian cancer who were sensitive to platinum-based chemotherapy.

Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.

Data from a recent analysis revealed that nearly 1 in 7 patients with hepatocellular carcinoma experience treatment delays, with higher odds observed in Black patients and those living in high poverty neighborhoods.

The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

Ciltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.